Recursion Pharmaceuticals (NASDAQ:RXRX) Trading Up 5% - What's Next?

Shares of Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX - Get Free Report) rose 5% during trading on Friday . The stock traded as high as $5.88 and last traded at $5.77. Approximately 6,133,700 shares traded hands during mid-day trading, a decline of 50% from the average daily volume of 12,364,041 shares. The stock had previously closed at $5.50.

Analysts Set New Price Targets

Several brokerages have recently commented on RXRX. Morgan Stanley cut their price target on shares of Recursion Pharmaceuticals from $10.00 to $8.00 and set an "equal weight" rating for the company in a report on Thursday, April 10th. KeyCorp cut their target price on Recursion Pharmaceuticals from $12.00 to $10.00 and set an "overweight" rating for the company in a research note on Wednesday, January 8th. Needham & Company LLC decreased their price target on Recursion Pharmaceuticals from $11.00 to $8.00 and set a "buy" rating on the stock in a research note on Tuesday. Cowen restated a "hold" rating on shares of Recursion Pharmaceuticals in a research report on Friday, February 28th. Finally, Leerink Partners decreased their target price on Recursion Pharmaceuticals from $7.00 to $6.00 and set a "market perform" rating on the stock in a research report on Friday, February 28th. Four analysts have rated the stock with a hold rating and two have issued a buy rating to the company's stock. According to MarketBeat, the company currently has a consensus rating of "Hold" and an average price target of $7.60.

Recursion Pharmaceuticals Stock Performance

The company has a market cap of $1.67 billion, a price-to-earnings ratio of -2.72 and a beta of 0.99. The company has a debt-to-equity ratio of 0.04, a quick ratio of 4.35 and a current ratio of 4.35. The company has a fifty day moving average of $5.75 and a two-hundred day moving average of $6.73.

Recursion Pharmaceuticals (NASDAQ:RXRX - Get Free Report) last announced its quarterly earnings results on Monday, May 5th. The company reported ($0.50) EPS for the quarter, missing analysts' consensus estimates of ($0.44) by ($0.06). Recursion Pharmaceuticals had a negative net margin of 579.52% and a negative return on equity of 76.56%. The firm had revenue of $14.75 million for the quarter, compared to analyst estimates of $18.12 million. During the same period in the previous year, the business posted ($0.39) earnings per share. The business's revenue for the quarter was up 7.2% compared to the same quarter last year. Equities research analysts anticipate that Recursion Pharmaceuticals, Inc. will post -1.57 EPS for the current year.

Hedge Funds Weigh In On Recursion Pharmaceuticals

Large investors have recently modified their holdings of the business. Accel Wealth Management bought a new stake in Recursion Pharmaceuticals in the fourth quarter worth approximately $310,000. Avanza Fonder AB acquired a new position in shares of Recursion Pharmaceuticals during the fourth quarter valued at about $580,000. Institute for Wealth Management LLC. bought a new position in shares of Recursion Pharmaceuticals during the 4th quarter worth about $3,928,000. Norges Bank bought a new stake in Recursion Pharmaceuticals in the 4th quarter valued at about $23,429,000. Finally, Invesco Ltd. raised its stake in Recursion Pharmaceuticals by 54.6% during the 4th quarter. Invesco Ltd. now owns 178,619 shares of the company's stock worth $1,207,000 after buying an additional 63,068 shares during the period. Institutional investors own 89.06% of the company's stock.

About Recursion Pharmaceuticals

Recursion Pharmaceuticals, Inc operates as a clinical-stage biotechnology company, engages in the decoding biology by integrating technological innovations across biology, chemistry, automation, data science, and engineering to industrialize drug discovery. The company develops REC-994, which is in Phase 2 clinical trial to treat cerebral cavernous malformation; REC-2282, which is in Phase 2/3 clinical trial for the treatment of neurofibromatosis type 2; REC-4881, which is in Phase 1b/2 clinical trial to treat familial adenomatous polyposis; REC-3964, which is in Phase 1 clinical trial to treat Clostridioides difficile infection; and REC-4881, which is in Phase 2 clinical trial to treat AXIN1 or APC mutant cancers.